UMMC Navigation

Cancer

Main Content

Inotuzumab Ozogamicin

This study is looking at the effects of an experimental drug in pediatric patients with relapsed leukemia.

Award title

Phase 2 study of inotuzumab ozogamicin in children and young adults with relapsed or refractory cd22+b acute lymphoblastic leukemia 

  • Principal Investigator: Dr. Anderson Collier

Who can participate

Those eligible to participate in this study include:
  • Children, adolescents, and young adults between the ages of 1-21 who have relapsed leukemia

For more information

  • Julie Hornaday, RN
    University of Mississippi Medical Center
    2500 N. State St.
    Jackson, MS 39216
    (601) 984-2712
  • IRB Number: 2017-0198